GLP-1 Agonists and Mental Health: The Brain-Body Connection

The first reports emerged on social media: people taking semaglutide for weight loss noticed something odd. Their constant mental chatter about food went quiet. Some felt calmer. Others reported anxiety. A few described feeling like different people entirely.

Then came the concerning headlines. In 2023, Iceland's Medicines Agency flagged reports of suicidal ideation in patients taking GLP-1 drugs. The European Medicines Agency launched an investigation. The FDA followed. Suddenly, drugs that millions were taking to manage diabetes and obesity were under scrutiny for psychiatric effects no one had anticipated.

The reality is more complex than the headlines suggest. GLP-1 receptor agonists don't just work in the pancreas and gut. They cross into the brain, binding to receptors in regions that control reward, emotion, stress response, and memory. The same mechanisms that reduce appetite and lower blood sugar also alter dopamine signaling, quiet neuroinflammation, and may reshape the neural circuits that govern mood.

This is the emerging science of GLP-1 and mental health: a field where large observational studies show reduced depression risk, randomized trials find no psychiatric harm, preclinical research reveals neuroprotective mechanisms, and patients report psychological shifts that blur the line between biology and identity.

GLP-1 Receptors in the Brain: More Than Metabolism

GLP-1 was long understood as a metabolic hormone. Produced in the gut after eating, it triggers insulin release, slows gastric emptying, and signals satiety. The development of GLP-1 receptor agonists for diabetes treatment seemed straightforward: mimic the hormone, control blood sugar.

But GLP-1 receptors aren't confined to the pancreas and digestive tract. They're distributed throughout the central nervous system in regions that have nothing to do with glucose metabolism.

Where the Receptors Are

In human brain tissue, GLP-1 receptors are expressed throughout the cerebral cortex, hypothalamus, hippocampus, amygdala, caudate putamen, and globus pallidus. Each of these regions serves distinct functions:

Hypothalamus: The metabolic control center. GLP-1 receptors here are densely concentrated in the arcuate nucleus, paraventricular nucleus, and ventromedial hypothalamus — regions that regulate hunger, energy expenditure, and stress hormone release.

Hippocampus: Critical for memory formation and mood regulation. GLP-1 signaling in the hippocampus influences synaptic plasticity, the process by which neurons strengthen or weaken their connections based on experience. Disrupted hippocampal function is a hallmark of depression.

Amygdala: The brain's emotional processing hub. Animal studies show robust GLP-1 receptor expression in the central, capsular, and lateral regions of the amygdala, areas involved in fear conditioning, threat detection, and emotional learning.

Ventral tegmental area and nucleus accumbens: The dopamine reward pathway. GLP-1 neurons project directly to these regions, where they modulate dopamine release in response to food, drugs, and other rewarding stimuli.

This distribution suggests that GLP-1's role in the brain extends far beyond appetite suppression. The receptor sits at the intersection of metabolic regulation, emotional processing, reward signaling, and cognitive function.

The Blood-Brain Barrier Question

Whether peripheral GLP-1 agonists like semaglutide and liraglutide actually reach these brain receptors is more nuanced than early research suggested.

The blood-brain barrier is a selective gate that prevents most large molecules from entering brain tissue. Native GLP-1 doesn't cross it effectively. But GLP-1 receptor agonists can gain access to certain brain regions through specialized uptake around the circumventricular organs — areas where the blood-brain barrier is naturally leaky. These include the area postrema, a brainstem region rich in GLP-1 receptors that relays signals to other parts of the brain.

There's also evidence of receptor-mediated transport across brain endothelial cells, a process where the drug binds to receptors on the barrier itself and gets shuttled through. This means that while semaglutide and liraglutide don't flood the entire brain like they do peripheral tissues, they reach enough critical regions to exert meaningful central effects.

The clinical relevance is clear: GLP-1 receptor agonists like liraglutide, exenatide, and dulaglutide have demonstrated safety and potential efficacy in early-phase clinical trials for neurodegenerative diseases, outcomes that require direct action in brain tissue.

The Depression Data: What the Studies Actually Show

When researchers started analyzing electronic health records for psychiatric outcomes in GLP-1 users, they found a pattern that surprised them. People taking these drugs for diabetes or obesity appeared to have lower rates of depression and anxiety than matched controls taking other medications.

Large Observational Studies

A 2024 study in Nature Medicine analyzed data from patients with obesity receiving GLP-1 receptor agonists. While some signals raised concern (the study found a 98% increased risk of any psychiatric disorders in one analysis), the authors emphasized that interpretation requires caution given the observational design and potential confounding factors.

But the most striking finding came from an NIH-funded analysis of electronic health records covering more than 1.8 million patients. People taking semaglutide were up to 73% less likely to report suicidal thoughts than those taking other weight loss or diabetes medications. The protective effect appeared across multiple patient subgroups.

A 12-month propensity-score matched cohort study published in eClinicalMedicine examined neuropsychiatric outcomes in semaglutide users with type 2 diabetes. The conclusion: semaglutide was not associated with higher risk of adverse neuropsychiatric outcomes compared to other antidiabetic medications.

Randomized Controlled Trials

The gold standard for evaluating drug safety is the randomized controlled trial. A post-hoc analysis of the STEP 1, 2, 3, and 5 trials published in JAMA Internal Medicine examined psychiatric outcomes in participants without known major psychopathology. Across 68 to 104 weeks of treatment, semaglutide-treated participants showed no increased risk of moderately severe depressive symptoms, suicidal thoughts, or suicidal behavior compared to placebo. In fact, 1% or fewer of participants in either group reported suicidal ideation during the trials.

A 2026 systematic review in Diabetes, Obesity and Metabolism analyzed 80 randomized clinical trials including 107,860 participants. The meta-analysis found no significant association between GLP-1 receptor agonist use and either serious or non-serious psychiatric adverse events compared to placebo.

The Paradox

Here's the puzzle: large observational datasets suggest a protective effect against depression, yet some pharmacovigilance databases show increased reporting of psychiatric adverse events. A 2025 study in ScienceDirect found significant signals for anxiety, depressed mood disorders, and suicidality associated with semaglutide in adverse event reports.

The explanation likely lies in reporting bias and baseline psychiatric risk. People experiencing negative psychiatric effects are more likely to report them than those who feel better. And GLP-1 drugs are increasingly prescribed to populations with existing mental health conditions — individuals already at elevated risk. Some data suggest a potential risk signal among individuals concurrently using antidepressants or benzodiazepines, groups with pre-existing psychiatric vulnerability.

The clinical trial data, which controls for these biases, provides reassurance. But it also highlights that individual responses vary considerably. Some people feel better. Some feel worse. Most experience no psychiatric change at all.

The Suicidal Ideation Controversy: What Regulators Found

In July 2023, the European Medicines Agency announced it was reviewing 150 reports of suicidal thoughts or self-harm in patients taking liraglutide or semaglutide. The news spread rapidly. Patients stopped their medications. Physicians hesitated to prescribe.

The FDA launched its own investigation.

What the Investigations Revealed

In January 2024, both agencies released their findings. The European Medicines Agency concluded that "the available evidence does not support a causal association" between GLP-1 receptor agonists and suicidal thoughts or actions.

The FDA arrived at a similar conclusion. Their preliminary review found no clear link to suicidal ideation in the adverse event reporting system. However, the agency acknowledged it "cannot definitively rule out that a small risk may exist" and committed to ongoing monitoring.

The numbers provide context. As of December 2023, the FDA's adverse event reporting system had received 157 reports of suicidal ideation attributed to Ozempic and 18 attributed to Wegovy, compared to more than 2.6 million people prescribed semaglutide in the U.S. from January 2018 to September 2023. Even if all reports were causally related — which the FDA determined they were not — the incidence would be extremely low.

By 2026, the FDA requested removal of warnings about suicidal behavior and ideation from GLP-1 medications based on their completed review.

Why the Alarm Was Raised

Suicidal ideation is serious. Even a small signal warrants investigation. But the initial reports likely reflected several factors unrelated to direct drug toxicity:

Weight loss itself affects mood. Rapid weight loss can trigger psychological distress, particularly in individuals with a history of disordered eating or body image issues. The experience of dramatic physical transformation can be destabilizing, especially when identity has been closely tied to body size.

Loss of emotional coping mechanisms. For people who use food to manage stress, anxiety, or depression, GLP-1 drugs remove that coping strategy without replacing it. When the "food noise" goes silent, underlying emotional pain may become more acute.

Baseline psychiatric risk. People seeking treatment for obesity have higher rates of depression and anxiety than the general population. The association between GLP-1 use and psychiatric events may reflect the underlying condition being treated, not the drug itself.

A 2025 editorial in the American Journal of Psychiatry framed it clearly: "Association Versus Causation and the Need for Ongoing Surveillance." The reports were enough to warrant attention, but not enough to conclude the drugs cause suicidal ideation.

How GLP-1 Agonists May Reduce Depression: The Mechanisms

If GLP-1 receptor agonists do protect against depression in some individuals, what's the biological mechanism?

Several pathways have been identified in preclinical research and early clinical studies.

Neuroinflammation Reduction

Depression is increasingly understood as a neuroinflammatory condition. Chronic low-grade inflammation in the brain — driven by activated microglia, the immune cells of the central nervous system — disrupts neurotransmitter signaling, impairs neuroplasticity, and damages hippocampal neurons.

GLP-1 receptor agonists reduce microglial activation and suppress production of pro-inflammatory cytokines in animal models of depression. In mice subjected to chronic stress, administration of GLP-1 analogs decreased levels of IL-1β, IL-6, and TNF-α in brain tissue, markers of neuroinflammation that correlate with depressive behavior.

This anti-inflammatory effect appears to be independent of glucose metabolism. The neuroprotective properties of GLP-1 receptor agonists in Alzheimer's disease models work through reduced neuroinflammation and enhanced proteostasis, mechanisms that are not glucose-dependent.

BDNF Upregulation

Brain-derived neurotrophic factor (BDNF) is a protein that supports the survival of existing neurons and promotes the growth of new neurons and synapses. Low BDNF levels are consistently found in people with major depression. Antidepressants increase BDNF expression, an effect thought to underlie their therapeutic benefit.

GLP-1 receptor activation increases BDNF levels in the hippocampus and prefrontal cortex. In animal models, this upregulation correlates with enhanced synaptic plasticity — the ability of neurons to strengthen or weaken their connections — a process disrupted in depression.

The mechanism involves activation of the CREB signaling pathway, which increases transcription of the BDNF gene. In mice injected with amyloid-beta to model Alzheimer's pathology, the GLP-1 agonist exendin-4 increased phosphorylation of CREB and elevated BDNF levels, contributing to enhanced synaptic plasticity.

Neurotransmitter Modulation

GLP-1 regulates the release of serotonin, dopamine, gamma-aminobutyric acid (GABA), and glutamate, neurotransmitters that mediate mood, motivation, and stress response.

In the prefrontal cortex, GLP-1 signaling enhances glutamate transmission, which may improve cognitive function and counteract the blunted reward response seen in depression. In the amygdala, GLP-1 modulates GABAergic inhibition, potentially reducing anxiety and fear responses.

Hippocampal Neurogenesis

The hippocampus is one of the few brain regions where new neurons are generated throughout life. Depression is associated with reduced hippocampal neurogenesis, and antidepressants promote it.

GLP-1 receptor agonists enhance hippocampal neurogenesis in animal models. This effect requires activation of the PI3K/Akt signaling pathway, the same pathway that mediates neuronal survival and growth in response to BDNF.

In a mouse model of type 2 diabetes, semaglutide administration mitigated depressive- and anxiety-like behaviors while enhancing cognitive function. The effect was linked to changes in the gut microbiome, suggesting the microbiota-gut-brain axis as another pathway through which GLP-1 drugs may influence mood.

Clinical Evidence in Humans

A 16-week randomized clinical trial evaluated semaglutide in adults with major depressive disorder. While the drug did not improve the primary outcome — executive function — it did improve global cognition and was safe in patients with MDD. The trial demonstrated feasibility of using GLP-1 agonists in psychiatric populations, though efficacy for core depressive symptoms remains to be established.

A systematic review of preclinical and clinical investigations found that 15 out of 18 preclinical studies (83%) reported significant antidepressant-like effects, associated with enhanced neuroplasticity, reduced neuroinflammation, and neurotransmitter alterations. The clinical data, however, remains limited.

GLP-1 and Anxiety: The Amygdala Connection

Anxiety disorders are the most common psychiatric conditions worldwide. Like depression, they involve dysregulated brain circuits, particularly in the amygdala.

The amygdala processes emotional information and orchestrates physiological responses to threat. Hyperactivity in the amygdala is a consistent finding in people with generalized anxiety disorder, panic disorder, and post-traumatic stress disorder.

GLP-1 receptors in the amygdala may modulate this threat response. In animal models, GLP-1 signaling in the central and lateral amygdala influences fear conditioning and anxiety-like behavior. Blocking GLP-1 receptors in these regions increases anxiety; activating them reduces it.

The clinical data on GLP-1 agonists and anxiety is mixed. Some observational studies report increased anxiety. A pharmacovigilance study found significant signals for anxiety (aROR: 1.26) with semaglutide. But a nationwide, population-based cohort study found decreased risk of anxiety in diabetic patients receiving GLP-1 receptor agonists.

The discrepancy may reflect individual differences in baseline anxiety, concurrent stressors, and the psychological impact of weight loss. For some, reduced "food noise" and improved metabolic health lower anxiety. For others, loss of food as a coping mechanism or the stress of rapid physical change increases it.

The "Ozempic Personality": Identity, Mood, and the Food-Mood Connection

In online forums and social media, a new term has emerged: "Ozempic personality." People describe feeling calmer, less impulsive, more subdued. Some report lower libido. Others say they've lost interest in activities they once enjoyed.

"Ozempic personality" isn't a medical term, and it's not a documented side effect. But the experiences patients describe are real, and they point to the complex relationship between metabolism, reward, and identity.

The Food Noise Phenomenon

One of the most commonly reported effects of GLP-1 agonists is the silencing of "food noise" — the constant background hum of thoughts about food. What to eat. When to eat. Cravings. Planning the next meal.

GLP-1 drugs weaken cravings and silence this mental chatter, so that people don't need willpower to resist food. It simply becomes less interesting.

For some, this is liberating. The mental bandwidth once consumed by food-related rumination becomes available for other things. But for others, particularly those who used food to regulate emotions, the silence is unsettling.

Emotional Eating and Weight Loss

Research shows that individuals who eat in response to negative emotions are less likely to lose weight on GLP-1 therapy than those who eat in response to external stimuli like food sights and smells.

The explanation: emotional eating is strongly influenced by psychological factors that aren't directly addressed by GLP-1 receptor agonist therapy. When people emotionally eat, that's their coping mechanism. When a GLP-1 medication shuts down food noise, the coping mechanism disappears, but the underlying emotions remain. People are suddenly faced with feelings they previously managed by eating.

This can precipitate a psychological crisis. Without the buffer of food, anxiety, sadness, anger, or loneliness feel more acute. Some people develop new coping strategies. Others struggle.

Identity and Physical Transformation

GLP-1 drugs reshape identity and mental health, not just bodies. For individuals who have lived in larger bodies for most of their lives, rapid weight loss can trigger profound identity shifts.

The experience of being treated differently — with more respect, attention, or kindness — after weight loss can be psychologically painful. It sharpens awareness of how devalued people were before, a realization that's harmful and difficult to integrate.

Some describe feeling like a different person. Quieter. Less gregarious. More anxious in social situations that previously felt comfortable. Whether these changes reflect direct neurobiological effects of the drug, the psychological consequences of weight loss, or the removal of food as a social and emotional anchor is impossible to disentangle in individual cases.

Are the Changes Permanent?

There's no evidence to suggest that GLP-1 drugs cause permanent changes to personality. What many people experience are temporary shifts in mood, energy, or emotional responses tied to appetite suppression and weight loss. When the drug is discontinued, food noise typically returns, appetite rebounds, and weight is often regained unless other interventions are in place.

But the psychological experience of transformation — of seeing oneself and being seen differently — may leave lasting effects on self-concept and relationships, independent of the drug itself.

GLP-1 and Addiction: Alcohol, Drugs, and the Reward Pathway

One of the most intriguing findings in recent GLP-1 research is the effect on addiction and substance use.

Anecdotal reports emerged first: people on semaglutide for weight loss noticed they drank less alcohol. Some quit entirely without trying. The same was reported for cigarettes, cannabis, and even compulsive shopping.

The clinical data followed.

Alcohol Use Disorder

A randomized clinical trial published in JAMA Psychiatry in 2025 tested subcutaneous semaglutide in adults with alcohol use disorder. Low-dose semaglutide reduced the amount of alcohol consumed during a laboratory self-administration task, with medium to large effect sizes. Semaglutide treatment significantly reduced drinks per drinking day and weekly alcohol craving, and predicted greater reductions in heavy drinking over time.

A systematic review and meta-analysis in eClinicalMedicine found that GLP-1 receptor agonists — particularly semaglutide and liraglutide — were associated with significant reductions in alcohol intake. Pooled analysis demonstrated a significant reduction in AUDIT scores (mean difference −7.81 points), a validated measure of alcohol consumption and problems.

In preclinical studies, semaglutide reduced alcohol intake and relapse-like drinking in male and female rats. Neuroimaging revealed attenuated alcohol cue reactivity and dopaminergic signaling. Behavioral, neurochemical, and molecular experiments showed that semaglutide reduced alcohol-related responses via dopamine mechanisms within the nucleus accumbens.

The Dopamine Reward Pathway

The mechanism is becoming clear. By targeting GLP-1 receptors, the drugs blunt dopamine release and reduce reward signaling, meaning people feel less driven to seek out food, alcohol, or drugs.

GLP-1 is synthesized in specific brainstem neurons and projects to areas involved in reward regulation, such as mesocortical limbic dopamine pathways, ventral tegmental area, and nucleus accumbens. When GLP-1 receptors in these regions are activated, dopamine signaling is dampened.

In mouse models, semaglutide attenuated the ability of alcohol to cause hyperlocomotion and to elevate dopamine in the nucleus accumbens. This is the same mechanism thought to underlie the drug's effect on food intake: it makes rewarding stimuli less rewarding.

Implications for Behavioral Addictions

If GLP-1 agonists blunt reward signaling broadly, the implications extend beyond substance use. Preliminary reports suggest effects on gambling, compulsive shopping, and internet use, though controlled studies are lacking.

This raises both therapeutic potential and concern. Dampened reward signaling could reduce harmful compulsive behaviors. But it could also flatten emotional experience more generally, reducing the pleasure derived from activities that bring meaning and joy.

Understanding the individual variability in these effects — who experiences them, under what conditions, and whether they persist — is a critical area for future research.

GLP-1 in Neurodegenerative Diseases: Parkinson's and Alzheimer's

The neuroprotective effects of GLP-1 receptor agonists extend beyond mood and addiction to neurodegenerative diseases.

Parkinson's Disease

A double-blind, placebo-controlled trial (n = 59) showed that exenatide led to significant effects on Parkinson's disease-related motor expression over a 9-month period. The improvement persisted after discontinuation, suggesting a disease-modifying effect rather than symptomatic relief.

NLY01, a GLP-1 receptor agonist designed for brain penetration, was evaluated in early untreated Parkinson's disease in a randomized, double-blind, placebo-controlled trial. The drug showed promise in slowing disease progression, though larger trials are needed.

The mechanism likely involves reduction of neuroinflammation and protection of dopaminergic neurons in the substantia nigra, the brain region that degenerates in Parkinson's disease.

Alzheimer's Disease

The results in Alzheimer's have been more mixed. Two large randomized, placebo-controlled trials of oral semaglutide in people with Alzheimer's showed no slowing of disease progression compared with placebo, according to Novo Nordisk. However, the drug did improve unspecified markers of the disease.

More encouraging results came from the ELAD trial, which enrolled 204 participants with mild to moderate Alzheimer's who received daily injections of liraglutide or placebo for 52 weeks. While the primary outcome — cerebral glucose metabolism — showed no significant difference, liraglutide may exert its effect via neuroprotective mechanisms rather than symptomatic improvement.

Real-world pharmacoepidemiologic data published in Alzheimer's & Dementia in 2025 found that initiation of GLP-1 receptor agonists was associated with a statistically significant reduced risk of Alzheimer's disease (hazard ratio ≤ 0.69, p < .001).

The divergence between randomized trials and observational data may reflect differences in disease stage, duration of treatment, or confounding by indication. People who receive GLP-1 drugs may have better overall metabolic health or healthcare engagement, factors that independently reduce dementia risk.

Neuroprotective Mechanisms

The pathways through which GLP-1 agonists may protect against neurodegeneration include:

• Reduced neuroinflammation: Suppression of microglial activation and pro-inflammatory cytokine production
• Enhanced proteostasis: Improved clearance of misfolded proteins like amyloid-beta and tau
• Mitochondrial function: Protection against oxidative stress and energy failure in neurons
• Synaptic plasticity: Upregulation of BDNF and enhancement of synaptic strength

These mechanisms are not glucose-dependent, meaning they could benefit people without diabetes.

What Patients and Clinicians Should Know

The relationship between GLP-1 receptor agonists and mental health is complex, evolving, and highly individual.

The Evidence in Summary

Depression: Large observational studies suggest a protective effect. Randomized trials show no increased risk. Preclinical research reveals plausible mechanisms through neuroinflammation reduction, BDNF upregulation, and neurotransmitter modulation. Clinical trials specifically targeting depression are underway.

Suicidal ideation: Regulatory investigations by the FDA and EMA found no causal link. Large-scale data show reduced risk in semaglutide users. Adverse event reports likely reflect baseline psychiatric risk and the psychological impact of weight loss.

Anxiety: Mixed evidence. Some studies show reduced risk; others show increased reporting. Individual responses vary widely.

Alcohol and addiction: Emerging evidence supports significant reductions in alcohol consumption and craving. The mechanism involves dampened dopamine reward signaling. Effects on other addictive behaviors are being investigated.

Emotional eating and identity: The silencing of food noise can unmask underlying emotional issues. Weight loss can trigger identity shifts and psychological distress in some individuals.

Neurodegenerative diseases: Promising signals in Parkinson's disease. Mixed results in Alzheimer's. Neuroprotective mechanisms are biologically plausible and supported by preclinical research.

Individual Variability

Not everyone responds the same way. Some people feel better on GLP-1 agonists. Some feel worse. Most experience no psychiatric change.

Factors that may influence response include:

• Baseline psychiatric health: Individuals with pre-existing depression or anxiety may be more vulnerable to mood changes
• Emotional eating patterns: Those who use food to manage emotions may struggle more when appetite is suppressed
• Rate of weight loss: Rapid transformation can be psychologically destabilizing
• Social and psychological support: Access to therapy, community, and coping strategies beyond food

Clinical Monitoring

For patients starting GLP-1 therapy, particularly for weight loss:

• Screen for psychiatric history before initiating treatment
• Monitor mood and anxiety in early weeks and months
• Ask about coping mechanisms — how does the patient manage stress, and what role does food play?
• Be alert to identity distress in individuals undergoing rapid weight loss
• Consider concurrent psychological support for those with emotional eating patterns or body image concerns
• Recognize that withdrawal of the drug may trigger weight regain, mood changes, and return of food preoccupation

The Bigger Picture

GLP-1 receptor agonists have fundamentally changed how we think about obesity, metabolism, and now, the brain. They've revealed that the systems governing hunger, reward, mood, and cognition are deeply intertwined.

The drugs don't just treat diabetes or reduce weight. They alter how the brain responds to food, stress, and pleasure. For some, that's therapeutic. For others, it's unsettling. For most, it's somewhere in between.

As millions more people begin GLP-1 therapy, a clearer picture of the psychiatric effects will emerge. Large-scale, long-term studies with systematic psychiatric assessment are needed. Trials specifically targeting mental health conditions — depression, anxiety, PTSD, addiction — are underway and will provide critical data.

In the meantime, the message is nuanced: GLP-1 agonists appear safe from a psychiatric standpoint for most people. The risk of serious psychiatric harm is low. But individual experiences vary widely, and psychological effects — both positive and negative — are real.

For patients and clinicians navigating this new landscape, awareness, monitoring, and open communication are essential. The brain-body connection is not a metaphor. It's biology. And GLP-1 receptor agonists are teaching us just how deeply metabolism and mind are intertwined.

References

1. National Academies of Sciences, Engineering, and Medicine. (2025). GLP-1 Mechanisms in the Brain - Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK615028/

2. Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2024). Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry. The Journal of Neuropsychiatry and Clinical Neurosciences. https://psychiatryonline.org/doi/full/10.1176/appi.neuropsych.20230226

3. Cork, S. C. (2022). Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics. British Journal of Pharmacology, 179(4), 600-621. https://pmc.ncbi.nlm.nih.gov/articles/PMC8820188/

4. Salameh, T. S., et al. (2020). Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process. Frontiers in Physiology. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00555/full

5. Isaacs, D., et al. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 14, 24965. https://www.nature.com/articles/s41598-024-75965-2

6. National Institutes of Health. (2024). People taking semaglutide had lower risk of suicidal thoughts. NIH Research Matters. https://www.nih.gov/news-events/nih-research-matters/people-taking-semaglutide-had-lower-risk-suicidal-thoughts

7. McIntyre, R. S., et al. (2024). 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine, 74, 102704. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00305-5/fulltext

8. Rubino, D. M., et al. (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Internal Medicine. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2823084

9. Sa, N. R., et al. (2026). Psychiatric effects of GLP‐1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity and Metabolism. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70198

10. Edwards, E. (2024). Ozempic isn't linked to suicidal thoughts, U.S. and European health agencies find. NBC News. https://www.nbcnews.com/health/health-news/ozempic-isnt-linked-suicidal-thoughts-us-european-health-agencies-find-rcna147578

11. Hollingsworth, H. (2023). Should Ozempic come with a warning about a risk of suicidal thoughts? NBC News. https://www.nbcnews.com/health/health-news/ozempic-wegovy-reports-suicidal-thoughts-rcna93919

12. Howard, J. (2024). Ozempic, Wegovy not associated with higher risk of suicidal ideation in large review of US health records. CNN. https://www.cnn.com/2024/01/05/health/ozempic-wegovy-suicidal-ideation/index.html

13. Gao, Y., et al. (2020). Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in Pharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC7456867/

14. Cai, H. Y., et al. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Pharmaceutics, 14(9), 1905. https://pmc.ncbi.nlm.nih.gov/articles/PMC9455625/

15. Cukierman-Yaffe, T., et al. (2025). Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Journal of Affective Disorders, 386, 157-164. https://www.sciencedirect.com/science/article/abs/pii/S2666634025003435

16. Leggio, L., et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811

17. Klausen, M. K., et al. (2025). Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. eClinicalMedicine. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00579-6/fulltext

18. Bornebusch, A. B., et al. (2023). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. eBioMedicine, 93, 104642. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00207-4/fulltext

19. Volkow, N. D., & Wiers, C. E. (2024). Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. American Journal of Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC12372146/

20. Brown University School of Public Health. (2025). A turning point in addiction psychiatry? https://sph.brown.edu/news/2025-07-24/brain-science-glp-1s-addiction

21. Frontiers. (2025). People on Ozempic who eat to regulate emotions less likely to lose weight. https://www.frontiersin.org/news/2025/09/17/people-ozempic-eat-emotions-less-likely-lose-weight-frontiers-clinical-diabetes-healthcare

22. Noom. (2025). Ozempic Personality: Exploring Potential Mood and Emotional Changes. https://www.noom.com/blog/weight-management/ozempic-personality-exploring-potential-mood-and-emotional-changes/

23. Calm. (2025). Can Ozempic really change your personality? What science actually says. https://www.calm.com/blog/ozempic-personality

24. Psychology Today. (2025). Ozempic Is Changing More Than Weight. https://www.psychologytoday.com/us/blog/diagnosis-human/202512/ozempic-is-changing-more-than-weight

25. Manolopoulos, A., et al. (2025). GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions. Frontiers in Endocrinology. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1708565/full

26. NeurologyLive. (2025). Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook. https://www.neurologylive.com/view/repositioning-glp-1-drugs-neurologic-disease-evidence-advances-outlook

27. Athauda, D., & Foltynie, T. (2024). Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making? Neuropharmacology, 251, 109922. https://www.sciencedirect.com/science/article/pii/S0028390824001217

28. AAAS Science. (2025). Popular obesity drug fails in hotly anticipated Alzheimer's trials. https://www.science.org/content/article/popular-obesity-drug-fails-hotly-anticipated-alzheimer-s-trials

29. Edison, P., et al. (2025). Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nature Medicine. https://www.nature.com/articles/s41591-025-04106-7

30. Zhang, Y., et al. (2025). Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease. Alzheimer's & Dementia. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70639